These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6101171)

  • 1. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation.
    Wilson S; Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1983 May; 46(5):377-82. PubMed ID: 6101171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.
    Wilson S; Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1983 May; 46(5):383-7. PubMed ID: 6101172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG.
    Toyka KV; Löwenadler B; Heininger K; Besinger UA; Birnberger KL; Fateh-Moghadam A; Heilbronn E
    J Neurol Neurosurg Psychiatry; 1980 Sep; 43(9):836-42. PubMed ID: 6252294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect.
    Mossman S; Vincent A; Newsom-Davis J
    J Neurol Sci; 1988 Mar; 84(1):15-28. PubMed ID: 2835437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions.
    Stanley EF; Drachman DB
    Science; 1978 Jun; 200(4347):1285-7. PubMed ID: 663610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody to acetylcholine receptor increases degradation of junctional and extrajunctional receptors in adult muscle.
    Reiness CG; Weinberg CB; Hall ZW
    Nature; 1978 Jul; 274(5666):68-70. PubMed ID: 661996
    [No Abstract]   [Full Text] [Related]  

  • 8. Acetylcholine receptor turnover in myasthenia gravis.
    Appel SH; Blosser JC; McManaman JL; Ashizawa T
    Am J Physiol; 1982 Jul; 243(1):E31-6. PubMed ID: 7091363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis: passive transfer from man to mouse.
    Toyka KV; Brachman DB; Pestronk A; Kao I
    Science; 1975 Oct; 190(4212):397-9. PubMed ID: 1179220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of myasthenia gravis as a disorder of acetylcholine receptors.
    Drachman DB; Pestronk A; Stanley EF
    Adv Cytopharmacol; 1979; 3():237-44. PubMed ID: 382787
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential susceptibility of young and old rat neuromuscular junctions to antibody-mediated AChR degradation in experimental autoimmune myasthenia gravis.
    Hoedemaekers A; Bessereau JL; Graus Y; Guyon T; Changeux JP; Berrih-Aknin S; Van Breda Vriesman P; De Baets M
    Ann N Y Acad Sci; 1998 May; 841():550-4. PubMed ID: 9668293
    [No Abstract]   [Full Text] [Related]  

  • 13. Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules.
    Sterz R; Hohlfeld R; Rajki K; Kaul M; Heininger K; Peper K; Toyka KV
    Muscle Nerve; 1986 May; 9(4):306-12. PubMed ID: 2423869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.
    Huijbers MG; Lipka AF; Plomp JJ; Niks EH; van der Maarel SM; Verschuuren JJ
    J Intern Med; 2014 Jan; 275(1):12-26. PubMed ID: 24215230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopathologic events at the endplate in myasthenia gravis.
    Ashizawa T; Appel SH
    Springer Semin Immunopathol; 1985; 8(3):177-96. PubMed ID: 2413561
    [No Abstract]   [Full Text] [Related]  

  • 16. The immunopathological basis of acetylcholine receptor deficiency in myasthenia gravis.
    Engel AG
    Prog Brain Res; 1979; 49():423-34. PubMed ID: 515440
    [No Abstract]   [Full Text] [Related]  

  • 17. Myasthenia gravis associated with etanercept therapy.
    Fee DB; Kasarskis EJ
    Muscle Nerve; 2009 Jun; 39(6):866-70. PubMed ID: 19373885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive transfer of seronegative myasthenia gravis to mice.
    Burges J; Vincent A; Molenaar PC; Newsom-Davis J; Peers C; Wray D
    Muscle Nerve; 1994 Dec; 17(12):1393-400. PubMed ID: 7969240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
    Toyka KV; Drachman DB; Griffin DE; Pestronk A; Winkelstein JA; Fishbeck KH; Kao I
    N Engl J Med; 1977 Jan; 296(3):125-31. PubMed ID: 831074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
    Berman PW; Heinemann SF
    J Immunol; 1984 Feb; 132(2):711-7. PubMed ID: 6690616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.